Aldeyra: positive Phase 2; cash runway into second half 2027

Aldeyra Therapeutics (ALDX) furnished an 8-K noting it issued a press release announcing positive Phase 2 results in alcohol-associated hepatitis, the prioritization of its RASP modulator product candidates, and an updated pipeline.

Accepted by SEC EDGAR 10/28/2025 - 07:00 AM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Aldeyra Therapeutics (ALDX) furnished an 8-K noting it issued a press release announcing positive Phase 2 results in alcohol-associated hepatitis, the prioritization of its RASP modulator product candidates, and an updated pipeline.

The company also reported an extension of its projected operational cash runway into the second half of 2027. The press release is included as Exhibit 99.1.

Insights

Biotech equity analyst

Positive Phase 2 signal and runway to the second half of 2027; details in Exhibit 99.1.

Aldeyra Therapeutics reported positive Phase 2 results in alcohol-associated hepatitis and highlighted prioritization of RASP modulators, alongside an updated pipeline. Early-stage efficacy signals can guide pipeline focus but require larger studies to confirm.

The company stated its projected operational cash runway extends into the second half of 2027, which frames funding visibility for ongoing development. Actual impact will depend on full data and development plans described in Exhibit 99.1.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did ALDX announce in its 8-K?

It disclosed a press release with positive Phase 2 results in alcohol-associated hepatitis, RASP modulator prioritization, an updated pipeline, and an extended cash runway.

Which program showed positive results for ALDX?

A Phase 2 clinical trial in alcohol-associated hepatitis reported positive results.

How long is Aldeyra’s projected cash runway?

The company stated its projected operational cash runway extends into the second half of 2027.

Where can I find more details on ALDX’s update?

The press release with details is filed as Exhibit 99.1.

What pipeline action did ALDX describe?

It reported prioritization of its RASP modulator product candidates and an updated pipeline.

What is ALDX’s trading symbol and exchange?

Common stock trades under ALDX on The Nasdaq Stock Market LLC.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

0001341235false00013412352025-10-282025-10-28

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 28, 2025

ALDEYRA THERAPEUTICS, INC.

(Exact name of Registrant as specified in its charter)

Delaware		001-36332		20-1968197
(State or other jurisdiction of incorporation)		(Commission File No.)		(IRS Employer Identification No.)

131 Hartwell Avenue, Suite 320

Lexington, MA 02421

(Address of principal executive offices and zip code)

Registrant’s telephone number, including area code: (781) 761-4904

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value per share		ALDX		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events.

On October 28, 2025, Aldeyra Therapeutics, Inc. (the “Company”) issued a press release (the “Press Release”) to announce positive results from a Phase 2 clinical trial in alcohol-associated hepatitis, the prioritization of the Company's RASP modulator product candidates, an updated pipeline, and the extension of the Company's projected operational cash runway into the second half of 2027. The Press Release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Aldeyra Therapeutics, Inc. Press Release dated October 28, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ALDEYRA THERAPEUTICS, INC.
By:	/s/ Todd C. Brady
	Name: Todd C. Brady M.D., Ph.D.
	Title: Chief Executive Officer

Dated October 28, 2025